Cartesian Therapeutics, Inc. (RNAC) Posts Positive Descartes-08 Retreatment Data; Phase 3 Topline 1Q27

Cartesian Therapeutics reported additional Descartes-08 retreatment data in MG showing mean MG-ADL reduction of 6.6 points at Month 12, with no new safety signals. Topline data from the Phase 3 AURORA trial are expected in 1Q27.Material DetailsContext by AI AnalystThis adds to earlier clinical sign…